Key Points
- CEO Daniel Perez sold 4,100 Hinge Health shares at an average price of $100.20, generating $410,820 and reducing his position by 50%. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Hinge Health reported strong quarterly results, with revenue rising 53% year over year to $212.82 million and EPS of $0.59, beating analyst estimates of $0.28.
- Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $105.33, while Hinge Health shares recently traded near their 12-month high.
Hinge Health Inc. (NYSE:HNGE - Get Free Report) CEO Daniel Perez sold 4,100 shares of the stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $100.20, for a total transaction of $410,820.00. Following the completion of the transaction, the chief executive officer owned 4,100 shares of the company's stock, valued at $410,820. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Daniel Antonio Perez also recently made the following trade(s):
- On Thursday, September 10th, Daniel Perez sold 150,000 shares of Hinge Health stock. The shares were sold at an average price of $89.44, for a total transaction of $13,416,000.00.
- On Thursday, September 10th, Daniel Perez sold 100,000 shares of Hinge Health stock. The shares were sold at an average price of $89.45, for a total transaction of $8,945,000.00.
Hinge Health Price Performance
Shares of NYSE:HNGE opened at $98.00 on Friday. The stock has a market cap of $7.91 billion, a price-to-earnings ratio of 76.56 and a beta of 1.37. Hinge Health Inc. has a 12 month low of $30.08 and a 12 month high of $100.36. The stock's 50 day moving average price is $90.69 and its 200 day moving average price is $70.98.
Hinge Health (NYSE:HNGE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.28 by $0.31. Hinge Health had a return on equity of 51.60% and a net margin of 15.15%.The firm had revenue of $212.82 million during the quarter. During the same period in the previous year, the business posted $0.59 earnings per share. The business's revenue for the quarter was up 53.0% compared to the same quarter last year. On average, sell-side analysts expect that Hinge Health Inc. will post 1.25 EPS for the current year.
Hedge Funds Weigh In On Hinge Health
Institutional investors have recently bought and sold shares of the stock. Vista Investment Partners LLC purchased a new position in shares of Hinge Health in the second quarter worth approximately $3,468,000. 11.2 Capital Management LLC purchased a new stake in shares of Hinge Health in the 2nd quarter valued at approximately $204,566,531. Alkeon Capital Management LLC boosted its stake in Hinge Health by 110.4% in the 4th quarter. Alkeon Capital Management LLC now owns 791,104 shares of the company's stock worth $36,747,000 after purchasing an additional 415,093 shares during the period. Schwartz Investment Counsel Inc. boosted its stake in Hinge Health by 28.3% in the 1st quarter. Schwartz Investment Counsel Inc. now owns 59,000 shares of the company's stock worth $2,275,000 after purchasing an additional 13,000 shares during the period. Finally, Estuary Capital Management LP purchased a new position in Hinge Health during the 1st quarter worth approximately $15,201,000.
Analyst Upgrades and Downgrades
A number of research firms recently issued reports on HNGE. Raymond James Financial lifted their target price on Hinge Health from $70.00 to $80.00 and gave the stock an "outperform" rating in a report on Monday, June 15th. Zacks Research lowered shares of Hinge Health from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 11th. Bank of America began coverage on shares of Hinge Health in a research note on Tuesday, September 29th. They issued a "buy" rating and a $110.00 price objective on the stock. Evercore reissued an "outperform" rating and set a $105.00 target price on shares of Hinge Health in a research note on Wednesday, August 5th. Finally, Barclays raised their target price on shares of Hinge Health from $97.00 to $100.00 and gave the stock an "overweight" rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, Hinge Health currently has an average rating of "Moderate Buy" and a consensus target price of $105.33.
Check Out Our Latest Research Report on HNGE
Hinge Health Company Profile
(
Get Free Report)
Hinge Health, Inc is a digital healthcare company focused on musculoskeletal (MSK) conditions, including back and joint pain. The company provides virtual care designed to help members manage pain, improve mobility and avoid or delay more invasive treatments.
Its platform combines a mobile application, motion-sensing technology, personalized exercise therapy, education and support from a care team that may include clinical specialists. Hinge Health offers programs for conditions such as chronic back pain, knee pain and other common MSK issues, with services generally provided through employers, health plans and other healthcare organizations.
Hinge Health was founded in 2015 and is headquartered in San Francisco, California.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
